AB Sciex: We will reshape India’s analytical sector

Updated on 22 February 2013

Tell us about your unique offerings to clients in India?
We are committed to responding to and meeting the growing needs of India's research and applied analytical testing communities. Our new product Swath will revolutionize the entire proteomics industry. It is changing the way scientists work in quantitative proteomics. Driven by superior speed and high-resolution performance of TripleTOF 5600 system in both mass spectrometer (MS) and MS/MS mode, this technique provides comprehensive quantitative data on every component in a sample in a single injection. As research evolves and new hypotheses are formed, one can re-interrogate a sample without the need to re-acquire data. Another product, AB Sciex 6500 series provides unprecedented level of sensitivity never before achieved in an LC/MS/MS system. Using the IonDrive technology, new innovations have been implemented in every part of the system.

How do you look at the opportunities in the Indian and Asia Pacific market?
We are looking at providing the country's highest-rated service and support to Indian customers, who analyze compounds, contaminants and proteins in various fields. We are also catering especially to the biosimilars and biological drug research companies and would like to mention that one of the India's leading companies in this area is using our technology. I find Indian market much bigger than other countries in the Asia Pacific. One thing that is unique about India is its CRO industry. The country is fast developing and the demand for technology is going to multiply in the coming years.

How has the growth been in the MS market?
The growth in the MS market has been tremendous. The demand has increased at an average of 20 percent every year and we are proud to say that we continue to hold a larger share of the market.

What is the future outlook for the company?
We have achieved the milestone of double digit growth record, which is pretty much unheard of. In the next five years, I see the company's growth to be atleast five times than that of today's size. Our motto in India is that we will always be there for India.

Previous 1 2 Next

Leave a Reply

Notify me of follow-up comments via e-mail address

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X